MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$34,852K
EPS
-$0.37
Unit: Thousand (K) dollars
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Total revenue-License
-
-
-26,706*
-
Total revenue
169,584
127,199
-
164,859
Total revenue-Product
-
-
156,394*
-
Cost of goods sold
2,174
1,950
2,554
1,585
Research and development
60,283
57,094
57,870
51,890
Selling, general and administrative
96,112
80,254
101,695
86,453
In-process research and development
-
-
-
0
Restructuring
-
-
-
0
Royalty expense
7,061
24,816
-
-
Total operating expenses
165,630
164,114
162,119
139,928
Operating income (loss)
3,954
-36,915
-32,431
24,931
Interest income
3,356
2,584
2,592
3,047
Interest expense
2,134
2,300
2,294
2,751
Other (expense) income, net
-169
-91
11,068
487
Inducement expense
40,008
-
-
-
Total other (expense) income, net
-38,955
193
11,366
783
Loss from continuing operations before income tax
-35,001
-36,722
-21,065
25,714
Income tax benefit (provision) on continuing operations
-204
-120
921
8
Loss from continuing operations, net of tax
-34,797
-36,602
-21,986
25,706
Loss from discontinued operations, net of tax
0
-500
24,715
0
Unrealized gain (loss) on defined benefit pension plan
-
-
-219
-
Net gain
-34,797
-37,102
2,729
25,706
Foreign currency translation gain (loss)
470
447
-243
-284
Unrealized loss on marketable debt securities
-525
-320
-111
42
Comprehensive gain
-34,852
-36,975
2,594
25,464
Basic EPS
-0.37
-0.4
0.029
0.29
Diluted EPS
-0.37
-0.4
0.034
0.28
Basic Average Shares
93,479,416
91,868,862
90,315,235
89,230,420
Diluted Average Shares
93,479,416
91,868,862
76,927,095
102,618,560
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Comprehensive gain
-$34,852K
(-173.91%↓ Y/Y)
Foreign currency
translation gain (loss)
$470K
(75.37%↑ Y/Y)
FILSPARI
$141,078K
Tiopronin Products
$20,274K
Net gain
-$34,797K
(-172.81%↓ Y/Y)
Unrealized loss on
marketable debt securities
-$525K
(-121.52%↓ Y/Y)
Product
$161,352K
(70.13%↑ Y/Y)
License
$8,232K
(-58.01%↓ Y/Y)
Loss from continuing
operations, net of tax
-$34,797K
(-172.81%↓ Y/Y)
Income tax benefit
(provision) on continuing...
-$204K
(-1120.00%↓ Y/Y)
Total revenue
$169,584K
(48.17%↑ Y/Y)
Loss from continuing
operations before income...
-$35,001K
(-174.84%↓ Y/Y)
Operating income (loss)
$3,954K
(131.26%↑ Y/Y)
Total operating
expenses
$165,630K
(30.32%↑ Y/Y)
Total other (expense)
income, net
-$38,955K
(-45729.41%↓ Y/Y)
Interest income
$3,356K
(2.10%↑ Y/Y)
Selling, general and
administrative
$96,112K
(26.10%↑ Y/Y)
Research and development
$60,283K
(22.12%↑ Y/Y)
Royalty expense
$7,061K
Cost of goods sold
$2,174K
(42.93%↑ Y/Y)
Inducement expense
$40,008K
Interest expense
$2,134K
(-25.02%↓ Y/Y)
Other (expense)
income, net
-$169K
(67.87%↑ Y/Y)
Buy us a coffee
Travere Therapeutics, Inc. (TVTX)
Travere Therapeutics, Inc. (TVTX)